title: Treatment of Wilson's disease: what are the relative roles of penicillamine, trientine, and zinc supplementation?
abstract: New options are available for the medical treatment of patients with Wilson's disease. Penicillamine is no longer the treatment of choice, as there is a growing experience with safer and more effective alternatives. Trientine may be the best choice for initial therapy in symptomatic patients requiring chelation therapy, and it may be even more effective when used in combination with zinc, which is recommended for maintenance therapy. Further studies are needed to determine the best therapy for pregnant patients with Wilson's disease, and whether combination therapy using trientine and zinc will be the next treatment of choice for all symptomatic patients with liver or neurologic disease.
authors.affiliation: Division of Liver Diseases, Department of Medicine, The Mount Sinai Medical Center, One Gustave L. Levy Place, Box 1633, New York, NY 10029-6574, USA. michael.schilsky@mssm.edu
authors.forename: M L
authors.initials: ML
authors.lastname: Schilsky
mesh_terms: D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors; D002614:Chelating Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy*; D006801:Humans; D008982:Molybdenum / Q000627:therapeutic use; D010396:Penicillamine / Q000627:therapeutic use*; D011247:Pregnancy; D014266:Trientine / Q000627:therapeutic use*; D015032:Zinc / Q000627:therapeutic use*
chemical_list: D002614:Chelating Agents; D008982:Molybdenum; C020809:tetrathiomolybdate; D000251:Adenosine Triphosphatases; D010396:Penicillamine; D015032:Zinc; D014266:Trientine